Venrock Healthcare Capital Partners

What Venrock Healthcare Capital Partners does

Venrock Healthcare Capital Partners (VHCP) is a later-stage healthcare investment program within the broader Venrock organization, which traces its origins to 1969. VHCP applies a venture capital-style long-term investment approach to two underserved segments of the healthcare market: small-capitalization public healthcare companies and late-stage private healthcare and biotechnology companies. Its stated focus areas are biotechnology and pharmaceuticals, with additional exposure to medtech.

The firm's product surface is investment management rather than a technology platform: it deploys capital via PIPE financings, private placements, underwritten public offerings, and crossover/late-stage private rounds, and provides strategic guidance to portfolio companies through clinical development, financings, and public-market navigation. The investment team is unusually credentialed, combining MDs from Harvard, Weill Cornell, Stanford, and UCSF with PhDs from Rockefeller and MBAs from Harvard, Stanford, and Wharton, alongside prior experience at Citadel Global Equities, MPM Capital, Blackstone Life Sciences, Vida Ventures, and J.P. Morgan Healthcare Investment Banking. The team operates primarily from Venrock's New York office at 7 Bryant Park, with a Silicon Valley office at 3340 Hillview Avenue, Palo Alto. VHCP does not market to the general public and limits its investor base to financially sophisticated limited partners.

VHCP generates revenue through traditional venture capital and crossover fund economics — management fees on assets under management plus carried interest on realized gains — neither of which is publicly disclosed. Portfolio activity in 2024-2026 demonstrates significant capital deployment: the firm led the €308M Series C for Tubulis (Europe's largest biotech financing), led the $220M Series D for CellCentric, led the $85M Korro Bio PIPE, and co-led financings for Angitia, Korsana Biosciences, Artiva Biotherapeutics, Century Therapeutics, Alto Neuroscience, and Cidara Therapeutics. The Venrock franchise's historical exits — AveXis ($8.7B to Novartis) and RayzeBio ($4.1B to Bristol Myers Squibb) — underpin the firm's brand and deal-flow positioning.

Name

Venrock Healthcare Capital Partners

Legal name

Venrock

Website

https://venrockcp.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

11–50 employees

Short description

Venrock Healthcare Capital Partners is a later-stage healthcare investment program within the Venrock franchise, deploying crossover and late-stage capital into small-cap public and late-stage private biotech and pharmaceutical companies, primarily through New York-based operations.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

akta.pro primary industry

Captive CVC Fund (Dedicated corporate fund structure) (FSANAHAB)

akta.pro secondary industry

Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)

Keywords

• Venture capital investment
• Healthcare investing
• Biotech funding
• Late-stage private equity
• Pharmaceutical investment

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Management Fees: Venrock Healthcare Capital Partners generates returns through equity investments in healthcare companies, with a focus on small-cap public equities and late-stage private healthcare companies. The firm employs a venture capital-like long-term investment approach.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Venrock Healthcare Capital Partners (VHCP) is a later-stage healthcare investment program that deploys capital into small-capitalization public companies and late-stage private healthcare companies using a venture capital-like long-term investment approach. The firm focuses on biotechnology, pharmaceuticals, and medtech companies, providing growth capital, strategic guidance, and operational support through clinical development, financings, and public market transitions.

Product overview

Venrock Healthcare Capital Partners operates as an investment firm with two distinct programs: (1) a traditional venture capital program focused on early-stage healthcare and technology investments, and (2) a later-stage healthcare program (VHCP) that applies venture capital-like long-term investment strategies to small-cap public companies and late-stage private healthcare companies. The firm does not offer a unified software product or platform, but rather investment management services across different funding stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Venrock Healthcare Capital Partners (VHCP) A later-stage healthcare investment program that implements a venture capital-like long-term investment approach to opportunities in small capitalization public companies and late-stage private healthcare companies, focused on biotechnology, pharmaceuticals, and medtech.

Quantifiable outcome

• AveXis acquired by Novartis for $8.7 billion
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• RA Capital Management: Healthcare-focused crossover fund that invests in both public and private biotech and medical companies. Highly comparable to VHCP's crossover strategy and healthcare focus.
• Perceptive Advisors: Healthcare-focused investment firm managing public equities and private investments in biotech and life sciences. Directly comparable crossover healthcare strategy and stage focus.
• Baker Bros. Advisors: Biotech-focused investment firm with substantial public and private healthcare portfolios. Highly comparable healthcare crossover strategy and small-cap public equity emphasis.
• Cormorant Asset Management: Healthcare-focused asset manager investing across public and private biotech markets. Comparable healthcare crossover focus and late-stage private deal activity.
• OrbiMed: Healthcare-dedicated investment firm with broader stage coverage from venture to public equities. Comparable healthcare focus with crossover elements across the capital stack.
• 5AM Ventures: Healthcare-focused venture capital firm investing in biotech companies. Comparable healthcare focus though with greater emphasis on earlier-stage opportunities.
• Atlas Venture: Early-stage biotech venture capital firm. Comparable healthcare focus but earlier-stage orientation than VHCP's late-stage mandate.
• ARCH Venture Partners: Venture capital firm focused on biotech and technology companies. Comparable healthcare focus with broader stage coverage including earlier-stage opportunities.
• Vida Ventures: Healthcare-focused venture capital firm investing in biotech companies. Comparable healthcare crossover focus; one team member (Kevin Kao) was previously a Vida Venture Fellow.

Broad incumbents

• New Enterprise Associates (NEA): Large diversified venture capital firm with a substantial healthcare practice. Broader portfolio than VHCP but with meaningful healthcare crossover overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/Venrock
• LinkedInlinkedin.com/company/venrock

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments109 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Venrock Healthcare Capital Partners